A Study of Single Patient Investigational Drug CPI-613 for Use in Treatment-Refractory, Metastatic Prostate Cancer


About this study

This is a single patient study of an investigational drug CPI-613 for treatment of metastatic prostate cancer. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Single patient study

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Eugene Kwon, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer